Sanctuary Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Sanctuary Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.8M	Sell	39,811 -9,549	-19%	-$4.23M	0.09%	225
2026 Q1	$22M	Sell	49,360 -444	-0.9%	-$207K	0.12%	186
2025 Q4	$22.6M	Buy	49,804 +3,551	+8%	+$1.53M	0.12%	181
2025 Q3	$18.1M	Sell	46,253 -917	-2%	-$383K	0.1%	209
2025 Q2	$21M	Buy	47,170 +1,303	+3%	+$600K	0.13%	170
2025 Q1	$22.2M	Buy	45,867 +2,036	+5%	+$949K	0.16%	147
2024 Q4	$19.2M	Buy	43,831 +928	+2%	+$430K	0.12%	179
2024 Q3	$19.3M	Buy	42,903 +13,529	+46%	+$6.5M	0.12%	183
2024 Q2	$11.7M	Buy	+29,374	New	+$12.7M	0.08%	253

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sanctuary Advisors's VRTX Position: Q2 2026 in Review

Sanctuary Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $4.23M and leaving 39,811 shares worth $19.8M. The position accounts for 0.09% of the portfolio, ranked #225.

Sanctuary Advisors first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $22.6M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Sanctuary Advisors held 39,811 shares of Vertex Pharmaceuticals worth $19.8M as of Q2 2026.
Sanctuary Advisors sold 9,549 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.23M.
Vertex Pharmaceuticals made up 0.09% of Sanctuary Advisors's portfolio in Q2 2026, its #225 holding.
Sanctuary Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Sanctuary Advisors's Vertex Pharmaceuticals position peaked at $22.6M in Q4 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.